undamentalytics Newsletter
Sign in

Cytomx Therapeutics, Inc. revenue

Cytomx Therapeutics, Inc.'s revenue was $76.2m in fiscal 2025, down 44.8% on the year before. Since fiscal 2013 ($888,000) it has grown at a compound 44.9% a year. Over the last twelve months it was $18.3m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue158157260276837531011387618
Growth on the year before—+471.7%+51.9%+95.1%+376.1%−16.9%−54.8%+154.4%−45.5%+42.5%+90.4%+36.4%−44.8%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Cytomx Therapeutics, Inc. $18.3m -87.0% -38.7%
Proqr Therapeutics N.V. $18.0m -12.1% —
Celularity Inc $18.7m -58.1% 7.2%
Scynexis Inc $19.2m 489.8% -47.9%
Keros Therapeutics, Inc. $14.9m -93.6% —
Janux Therapeutics, Inc. $24.0m 5367.0% 45.7%

Compare with peers

Head to head: CTMX vs PRQRCELU vs CTMXCTMX vs SCYX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cytomx Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cytomx Therapeutics, Inc.